发明名称 |
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies |
摘要 |
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. |
申请公布号 |
US9173880(B2) |
申请公布日期 |
2015.11.03 |
申请号 |
US201112986223 |
申请日期 |
2011.01.07 |
申请人 |
Regeneron Pharmaceuticals, Inc. |
发明人 |
Dix Daniel B.;Graham Kenneth S.;Kamen Douglas;Walsh Scott M. |
分类号 |
A61K39/395;A61K31/485;A61K9/00;C07K16/24;A61K47/18;A61K47/26 |
主分类号 |
A61K39/395 |
代理机构 |
Alston & Bird LLP |
代理人 |
Alston & Bird LLP ;Zahner Joseph |
主权项 |
1. A stable pharmaceutical formulation comprising: (i) 5 mg/mL to 200 mg/mL of a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R), wherein the antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO:18 and a light chain variable region having the amino acid sequence of SEQ ID NO:26; (ii) histidine at a concentration of from 25 mM to 100 mM; (iii) arginine at a concentration of from 25 mM to 50 mM; (iv) sucrose in an amount of from 3% to 10% w/v; and (v) polysorbate 20 in an amount of from 0.1% to 0.2%, wherein the formulation has a pH of about 5.8, about 6.0, or about 6.2, and at least 90% of the native form of the antibody is recovered after 1 month of storage at 45° C., as determined by size exclusion chromatography. |
地址 |
Tarrytown NY US |